The global protein diagnostics market, valued at approximately USD 4.9 billion in 2023, is poised for impressive growth, with a projected compound annual growth rate (CAGR) of 5.4%. According to the latest industry analysis by Future Market Insights, the market is expected to reach an estimated valuation of USD 8.3 billion by 2033, driven by advancements in diagnostic technologies and a growing emphasis on early disease detection.
Early diagnosis is becoming a cornerstone of modern healthcare, receiving increasing attention within the medical community. By identifying diseases sooner, healthcare systems can enhance care quality, expedite treatments, and reduce costs. These factors are expected to further transform healthcare delivery, with even better outcomes anticipated in the near future.
The rapid evolution of diagnostic technologies, particularly in the realm of artificial intelligence (AI), plays a critical role in early disease detection. AI systems are increasingly aiding in tasks such as diagnosis and treatment planning, reducing human errors, and enhancing accuracy. Notably, AI-driven visual pattern recognition software is showing early promise in achieving diagnostic accuracy on par with that of medical professionals, further improving diagnostic precision.
Governments across the globe are implementing robust screening programs for high-risk groups to bolster prevention efforts. These initiatives, including cancer screenings for breast, colon, and cervical cancers, have proven effective at detecting diseases early, leading to better patient outcomes. However, it is essential to balance the psychological and financial impacts of such screening programs with their health benefits.
In sum, the ongoing advancements in diagnostic technologies, the increasing focus on prevention, and the expanding role of AI in healthcare are all contributing to the growth of the global protein diagnostics market. As these trends continue to evolve, the demand for innovative and effective diagnostic solutions is expected to remain strong, positioning the market for continued growth in the coming years.
Key Takeaways from Market Study:
- Reagent Kits are the leading segment of products among end users, and held about 3% market share in 2022, the growing number of infectious diseases has led to their high adoption of reagent kits.
- By sample, serum is the most compatible because it is an abundant source of protein, accessibility, and stability than other samples. The segment contributes 4% value share to the global market in 2022.
- Disease diagnosis held the dominant market share of 0% among other applications in 2022, due to the recent rise of infectious diseases and hospital-acquired infections.
- Turbidimetry held a market share of 3% in 2022, owing to the factor that it shortens the assay time by enabling faster binding of the antibodies and antigen
- Hospital segment by end user accounted for a revenue share of 9% in the global market at the end of 2022. Hospitals are built to provide coordinated care across departments and specializations, which can be useful when many diagnostic tests are required to reach a diagnosis.
- By region, North America is leading in the global protein diagnostics market and is expected to continue to do so with a projected CAGR rate of 7% during the forecasted years.
“Increasing adoption of protein diagnostic testing for the identification of underlying diseases and early detection of chronic disease are the key drivers of the protein diagnostics market,” says an analyst of Future Market Insights.
Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trends!
Market Competition:
To expand their market share, major players in the protein diagnostics industry are adopting various growth strategies, including acquisitions, mergers, collaborations, and partnerships. These companies are also focused on enhancing their sales efforts and developing innovative products by leveraging new technologies.
- In October 2022, StoCastic, LLC, a premier artificial intelligence startup that delivers evidence-based decision support for hospital emergency departments (ED), has been acquired by Beckman Coulter Diagnostics.
- Biognosys, a prominent provider of next-generation proteomics technologies for drug discovery and development, reported in April 2021 that it has engaged in a strategic partnership with Siemens Healthineers, a multinational medical technology business, through its clinical laboratory in Berkeley, California. Biognosys’ expertise in unbiased biomarker discovery methods and solutions is combined with Siemens Healthineers’ skills in biomarker assay development, laboratory testing, and commercialization.
Key Companies Profiled:
Beckman Coulter, Inc.; Siemens Healthineers; F. Hoffmann-La Roche Ltd.; Agilent Technologies, Inc.; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Elabscience Biotechnology Inc.; Goldsite Diagnostics Inc.; Getein Biotech, Inc.; Randox Laboratories Ltd.; Hipro Biotechnology Co., Ltd.; Beijing Strong Biotechnologies, Inc.
Key Segments Covered in Protein Diagnostics Industry Research:
By Product:
- Analyzers
- Reagents
- Albumin Test Kits
- Alpha-1-Microglobulin Albumin Test Kits
- Alpha-2-Macroglobulin Albumin Test Kits
- C-Reactive Protein Test Kits
- Fibrinogen Test Kits
- Fibronectin Test Kits
- Haptoglobin Test Kits
- Kappa Light Chains Kits
- Lambda Light Chains Kits
- Transferrin Test Kits
- Alpha-1-Acid Glycoprotein Test Kits
- Alpha-1-Antitrypsin Test Kits
- Apolipoprotein B Test Kits
- Cystatin Test Kits
- Ferritin Test Kits
- Immunoglobulin Test Kits
- IgA
- IgE
- IgG
- IgG 1
- IgG 2
- IgG 3
- IgG 4
- IgM
- Lipoprotein Test Kits
- Others
- Calibrators & Controls Kits/Reagents
By Sample:
- Serum
- Plasma
- Urine
- Cerebrospinal Fluid
- Others
By Application:
- Drug Discovery and Development
- Antigen-Antibody Reaction
- Immunocomplex Reaction
- Protein Measurement
- Others
- Disease Diagnosis
- Cancer
- Infectious Disease
- Blood Coagulation
- Renal Function
- Liver Diseases
- Autoimmune Disorder
- Others
- Other Applications
By Technology:
- Turbidimetry
- Nephelometry
By End User:
- Hospital
- Diagnostic Labs
- Reference Labs
- Speciality Clinics/Standalone
By Region:
- North America
- Latin America
- China
- East Asia
- South Asia and the Pacific
- Western Europe
- Eastern Europe
- Central Asia
- Russia and Belarus
- Balkan and Baltic Countries
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube